Has Albert Rizzo received payments from drug or device companies?

Yes. Drug and device makers reported $161,804 in general payments to Albert Rizzo across 217 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Albert Rizzo did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Albert Rizzo come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Albert Rizzo

Pulmonary Disease · Newark, DENPI 1245283316

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $119,749 of the $161,804 with a category attached, or 74.0%. 17 manufacturers reported payments, led by GSK at 31.2% of the total. Reporting peaked in 2019 at $67,834 and has fallen 84.4% since, to $10,585 in 2025. Among pulmonary disease clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$161,804in general payments, 2019–2025

Across 217 payments — averaging $745.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$50K
Sanofi$28K
Boehringer Ingelheim$21K
Regeneron Healthcare Solutions, Inc.$17K
Mylan Specialty L.p.$13K
Modernatx, Inc.$8K
plus $25K from 11 others

What the payments were for

Consulting fees$27,55217%
Speaking & faculty fees$119,74974%
Travel & lodging$9,2206%
Food & beverage$5,2703%
Education$130%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	57	$50,407
Sanofi	19	$27,814
Boehringer Ingelheim	31	$21,408
Regeneron Healthcare Solutions, Inc.	29	$16,644
Mylan Specialty L.p.	17	$13,293
Modernatx, Inc.	5	$7,621
Sunovion Pharmaceuticals Inc.	12	$4,979
Pfizer	8	$4,529
Novartis	7	$4,224
Merck	5	$3,830
Astrazeneca UK Limited	2	$3,313
AstraZeneca	15	$2,457
Intuitive Surgical	2	$504
E.r. Squibb & Sons, L.L.C.	2	$291
Genentech USA, Inc.	3	$262
Circassia Inc.	2	$199
Vertex	1	$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$161,804 in reported general payments places this provider in the 95th percentile of 39 pulmonary disease providers in Delaware.

See all pulmonary disease providers in Delaware →

Other pulmonary disease in Newark

Haroon RajaNewark$44K
Ismael MatusNewark$27K
Naveed HasanNewark$3K
Theodora FynnNewark$2K
Sam ThomasNewark$2K
Irene SwiftNewark$2K
Donald CollinsNewark$2K
Sajjad AhmadNewark$749
Sonali BishnoiNewark$686
Farid MoosavyNewark$615

See the full list for Delaware →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →